Biomarker Driven Treatment of Selected NSCLC: ALK EML4; Crizotinib; Crizotinib Resistance; 2nd Generation Drugs

Event ESMO Preceptorship on NSCLC Singapore December 2016
Session Session 4 Biomarker Driven Treatment
Topics Non-Small-Cell Lung Cancer, Metastatic
Biomarkers
Drug Development
Presenter K. Nakagawa, JP